Corrigendum: A Universal Influenza Vaccine Can Lead to Disease Exacerbation or Viral Control Depending on Delivery Strategies
- 1VIM-INRA-Université Paris-Saclay, Jouy-en-Josas, France
- 2Institute of Microbiology of the Czech Academy of Sciences, v.v.i, Prague, Czech Republic
- 3INRA, UE1277, Plate-Forme d’Infectiologie Expérimentale PFIE, Nouzilly, France
- 4Institut Pasteur, Unité de Régulation Immunitaire et Vaccinologie, Equipe Labellisée Ligue Contre le Cancer, Paris, France
- 5INSERM U1041, Unité de Régulation Immunitaire et Vaccinologie, Département Immunologie, Paris, France
A corrigendum on
A Universal Influenza Vaccine Can Lead to Disease Exacerbation or Viral Control Depending on Delivery Strategies
by Bernelin-Cottet C, Deloizy C, Stanek O, Barc C, Bouguyon E, Urien C, et al. Front Immunol (2016) 7:641. doi:10.3389/fimmu.2016.00641
In the original article, there was an error in the CpG oligo-dinucleotide sequence used as adjuvant.
A correction has been made to the section “Materials and Methods”, paragraph “Antibodies and adjuvants”: CpG oligo-dinucleotides 5′-ggTGCATCGATTTATCGATTATCGATGCAGggggg-3′ with lower case letters for phosphorothioate linkages and upper case letters for phosphodiester linkages previously shown to be efficient in pigs (26) were bought from Sigma.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
Conflict of Interest Statement
CL, PS, and OS are inventors of the issued patent “A versatile delivery system for antigens or biologically active molecules.” EP 09290987.8-1222, 21.12.09. No license nor royalties. The other authors declare no conflict of interest.
Keywords: dendritic cells, swine, human, vaccines, routes of administration
Citation: Bernelin-Cottet C, Deloizy C, Stanek O, Barc C, Bouguyon E, Urien C, Boulesteix O, Pezant J, Richard C-A, Moudjou M, Costa BD, Jouneau L, Chevalier C, Leclerc C, Sebo P, Bertho N and Schwartz-Cornil I (2017) Corrigendum: A Universal Influenza Vaccine Can Lead to Disease Exacerbation or Viral Control Depending on Delivery Strategies. Front. Immunol. 8:831. doi: 10.3389/fimmu.2017.00831
Received: 23 June 2017; Accepted: 30 June 2017;
Published: 18 July 2017
Edited and Reviewed by: José Mordoh, Fundación Instituto Leloir, Argentina
Copyright: © 2017 Bernelin-Cottet, Deloizy, Stanek, Barc, Bouguyon, Urien, Boulesteix, Pezant, Richard, Moudjou, Costa, Jouneau, Chevalier, Leclerc, Sebo, Bertho and Schwartz-Cornil. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Isabelle Schwartz-Cornil, email@example.com
†Present address: Charlotte Deloizy, GenoSafe, Evry, France
‡These authors have equally contributed to this work.